German Detechgene Secures €3.2M for Mobile Lab Diagnostics

Cologne-based biotech startup Detechgene raised €3.2 million in its second Seed round. Neoteq ventures led the investment. This funding advances its mission to make molecular diagnostics fast and mobile.

Founded in 2022, Detechgene develops 'PCR to Go'. This mobile platform detects viruses, bacteria, and fungi. It delivers lab-accurate results in under 30 minutes without specialist equipment.

Advancing Decentralized Healthcare Diagnostics

The fresh capital will commercialise the platform and ramp up production. Detechgene targets both German and international healthcare markets. This technology offers rapid, accurate diagnoses at the point of need.

Healthcare systems globally face staffing shortages and diagnostic bottlenecks. Mobile diagnostic solutions address these critical challenges. For example, Abbott Laboratories and Roche also offer point-of-care testing. Detechgene's approach could transform patient outcomes.

NRW.BANK, Aquarius Invest, Meerkat Holding, and Campus Capital also participated. NRW.BANK has supported Detechgene since 2021. This investment supports DeepTech innovation in Germany. Furthermore, it highlights the growth of biotech startups in the region.

'PCR to Go' combines PCR robustness with rapid test ease. It requires no specialist equipment.